Genolution

Genolution Diluted EPS

The Diluted Earnings per Share of Genolution (225220.KQ) as of Oct 22, 2026 is -644.05 KRW. In the previous year, Diluted Earnings per Share was -378.02 KRW — a change of 70.37% (lower).

Diluted EPS

-644.05KRW

YoY

70.37%

Last updated:

Diluted Earnings per Share of Genolution is 2025 -644.05 KRW. Diluted Earnings per Share of Genolution was 2024 -378.02 KRW. It decreases by 70.37% lower compared to the previous year.

The Genolution Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
203.26 KRW
Jan 1, 2019
-47.72 KRW
Jan 1, 2020
3,349.59 KRW
Jan 1, 2021
1,881.28 KRW
Jan 1, 2022
808.90 KRW
Jan 1, 2023
-307.40 KRW
Jan 1, 2024
-378.02 KRW
Jan 1, 2025
-644.05 KRW
The Genolution Diluted EPS history
YEARDiluted EPSYoY
-644.05KRW+70.37%
-378.02KRW+22.98%
-307.40KRW-138.00%
808.90KRW-57.00%
1,881.28KRW-43.84%
3,349.59KRW-7,118.94%
-47.72KRW-123.48%
203.26KRW+106.12%
98.61KRW+535.88%
15.51KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Diluted Earnings per Share of Genolution is -644.05 KRW in 2025.

Diluted Earnings per Share of Genolution changed from -378.02 KRW to -644.05 KRW, representing a 70.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Genolution since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genolution

All Key Metrics — Genolution